Phase 3Data readout
Lanifibranor (Pan-PPAR)
Metabolic dysfunction-associated steatohepatitis (MASH)
IVA InventivaExpected catalystDecember 31, 2026Company guidance: Dec 31, 2026
Catalyst overview
Event details
- Drug or asset
- Lanifibranor (Pan-PPAR)
- Development stage
- Phase 3
- Event type
- Data readout
- Indication
- Metabolic dysfunction-associated steatohepatitis (MASH)
Research signalsPotential moverHigh management interest
Research summary
What is being tracked?
This catalyst tracks a Phase 3 data readout for Lanifibranor (Pan-PPAR) in Metabolic dysfunction-associated steatohepatitis (MASH). The expected timing is based on the latest available company guidance and may change.
Development notes
05/26/26:- NATiV3 Ph3 topline results now expected in Q4 2026.
Verification
Primary source
Confirm timing and program details against the company announcement or filing.